Letter: Legislation protects patients
Congresswoman Jaime Herrera Beutler’s, R-Camas, decision to look closely into unfair drug pricing practices is appreciated by patients who rely on the Medicare Part D benefit.
Long-term care (LTC) pharmacies dispense medication to those receiving care in skilled nursing and assisted living facilities, and provide clinical oversight services. Pharmacy benefit managers (PBM), third-party middlemen who oversee the pricing structure and reimbursement for most generic drugs dispensed by LTC pharmacies, control the cost of the drugs to both the patient and taxpayer.
PBM drug prices vary greatly and create reimbursement inequities. Pricing tactics used by PBMs are designed to maximize profit for PBMs and, in many cases, force LTC pharmacies to accept reimbursement below the cost to dispense. Prices for the same prescription drug on the same day vary considerably for different payers, raising questions about the relationship between price and actual market conditions.
Congresswoman Herrera Beutler’s decision to examine these loose ends through her support of the MAC Transparency Act (H.R. 244) will benefit Medicare beneficiaries in Washington. If PBMs continue to negotiate prices unchecked, it will increase costs to taxpayers and jeopardize patient care. I commend Herrera Beutler for co-sponsoring legislation that protects the interests of Medicare beneficiaries.
Click here to see the original article on The Columbian’s website.
Recent Posts
-
Senior Care Pharmacy Coalition Opposes CMS Final Rule on Minimum Staffing Standards for LTC Facilities
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care pharmacy sector, released a statement today regarding its opposition to the Centers for Medicare & Medicaid Services (CMS) final rule on minimum staffing standards for long-term care (LTC) facilities.
-
Senior Care Pharmacy Coalition Shares Comments with CMS Regarding Medicare Part D Restructuring Guidance: “Smoothing Provisions”
SCPC filed comments with CMS in response to their guidance on the implementation of the Medicare Part D restructuring portion of the Inflation Reduction Act (IRA).
-
Drug pricing efforts threaten ‘very existence’ of LTC pharmacies: reps
President Biden in his State of the Union address last week vowed to end “Big Pharma’s” grip on prescription drug pricing and cut costs for seniors and taxpayers by another $200 million.
But the president’s plans to expand his administration’s first-ever Medicare drug price negotiations could spell big trouble for the pharmacists who support seniors living in long-term care settings, advocates warned in response.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.